Featured Research

from universities, journals, and other organizations

Drug for Iron Overload Passes Major Safety Hurdle; May Benefit Patients with Thalassemia and Other Blood Disorders

Date:
February 23, 2000
Source:
The Children's Hospital Of Philadelphia
Summary:
An oral medication that may help patients with thalassemia and related blood disorders has fewer adverse effects on white blood cells than previously predicted. Deferiprone may help patients who do not benefit from conventional treatment for iron overload, a life-threatening complication of thalassemia.

FOR IMMEDIATE RELEASE February 22, 2000

Philadelphia, Pa. — An oral medication that may be helpful for patients with thalassemia and related blood disorders has fewer adverse effects on white blood cells than previously predicted. The drug, deferiprone, may help patients with thalassemia who do not benefit from the conventional treatment for iron overload, a life-threatening complication of their disease. A research team headed by a physician from The Children’s Hospital of Philadelphia announced the results of their multicenter study today in the British Journal of Haematology.

Thalassemia, an inherited disease of the blood in which hemoglobin fails to form properly, may be challenging to treat. Depending on its severity, the disease may require regular blood transfusions starting in early childhood and may cause an enlarged spleen, bone weakness and growth problems. The blood transfusions lead to the most serious complication, life-threatening multiple organ damage caused by accumulation of excessive iron. Therefore, patients with iron overload receive frequent treatments with desferrioxamine, which removes iron from the tissues. However, this drug is difficult to administer, because it must be pumped into the skin or bloodstream for an 8-to-12-hour period every night. Many patients do not comply with the arduous regimen, and others are unable to use it because of adverse reactions.

Therefore, for the past 20 years, researchers have been seeking an effective oral medicine for iron overload. The leading candidate has been deferiprone, but previous studies showed the medicine had a serious side effect called agranulocytosis, a sharp reduction in white blood cells. The current study measured the frequency of that side effect in 187 pediatric and adult patients at four sites, one at The Children’s Hospital of Philadelphia and the other three at thalassemia centers in Italy. The patients were unable or unwilling to use desferrioxamine.

Patients in the study received weekly blood tests to monitor deferiprone’s effects. Agranulocytosis occurred in only one patient, while nine patients had a milder reduction in white blood cells (neutropenia). "The study showed that toxicity to white blood cells is a rare side effect of deferiprone, and is not frequent enough to disqualify the drug as a potential treatment for iron overload," said Alan R. Cohen, M.D., chief of Hematology at The Children’s Hospital of Philadelphia and lead author of the study. "Although much research remains to be done, deferiprone might also be used to treat patients with other hemoglobin disorders, such as sickle cell disease, in which regular blood transfusions are often used."

Dr. Cohen added that since the study began, other possible side effects of deferiprone have been suggested, such as liver toxicity, and that further studies need to address such concerns. Like desferrioxamine, deferiprone is an iron chelator—a chemical that binds to excess iron and removes it from the body. "We are not proposing that deferiprone should replace desferrioxamine as a first-line therapy for iron overload," he said. "But it may become an option for patients who do not respond to desferrioxamine or who have severe adverse reactions to that conventional therapy."

The Children’s Hospital of Philadelphia, the nation’s first children’s hospital, is a leader in patient care, education and research. This 373-bed multispecialty hospital provides comprehensive pediatric services, including home care, to children from before birth through age 19. The hospital is second in the United States among all children’s hospitals in total research funding from the National Institutes of Health.


Story Source:

The above story is based on materials provided by The Children's Hospital Of Philadelphia. Note: Materials may be edited for content and length.


Cite This Page:

The Children's Hospital Of Philadelphia. "Drug for Iron Overload Passes Major Safety Hurdle; May Benefit Patients with Thalassemia and Other Blood Disorders." ScienceDaily. ScienceDaily, 23 February 2000. <www.sciencedaily.com/releases/2000/02/000222142015.htm>.
The Children's Hospital Of Philadelphia. (2000, February 23). Drug for Iron Overload Passes Major Safety Hurdle; May Benefit Patients with Thalassemia and Other Blood Disorders. ScienceDaily. Retrieved August 28, 2014 from www.sciencedaily.com/releases/2000/02/000222142015.htm
The Children's Hospital Of Philadelphia. "Drug for Iron Overload Passes Major Safety Hurdle; May Benefit Patients with Thalassemia and Other Blood Disorders." ScienceDaily. www.sciencedaily.com/releases/2000/02/000222142015.htm (accessed August 28, 2014).

Share This




More Health & Medicine News

Thursday, August 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Mini Pacemaker Has No Wires

Mini Pacemaker Has No Wires

Ivanhoe (Aug. 27, 2014) Cardiac experts are testing a new experimental device designed to eliminate major surgery and still keep the heart on track. Video provided by Ivanhoe
Powered by NewsLook.com
After Cancer: Rebuilding Breasts With Fat

After Cancer: Rebuilding Breasts With Fat

Ivanhoe (Aug. 27, 2014) More than 269 million women are diagnosed with breast cancer each year. Many of them will need surgery and radiation, but there’s a new simple way to reconstruct tissue using a patient’s own fat. Video provided by Ivanhoe
Powered by NewsLook.com
Blood Clots in Kids

Blood Clots in Kids

Ivanhoe (Aug. 27, 2014) Every year, up to 200,000 Americans die from a blood clot that travels to their lungs. You’ve heard about clots in adults, but new research shows kids can get them too. Video provided by Ivanhoe
Powered by NewsLook.com
Radio Waves Knock out Knee Pain

Radio Waves Knock out Knee Pain

Ivanhoe (Aug. 27, 2014) Doctors have used radio frequency ablation or RFA to reduce neck and back pain for years. But now, that same technique is providing longer-term relief for patients with severe knee pain. Video provided by Ivanhoe
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins